Phase II Trial to Evaluate the Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Capmatinib (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms METIMGAST
- 01 Feb 2023 Status changed from recruiting to suspended.
- 12 May 2022 Planned End Date changed from 1 Jun 2025 to 1 Oct 2025.
- 12 May 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2023.